Blog

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Photo from Jorge Cortes/X

Aug 18, 2024, 15:03

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Jorge Cortes, Director of the Georgia Cancer Center, shared on X about recent paper by him as first author titled “Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)” published on Taylor and Francis Online.

Authors: Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer and Justin M. Watts

“Published the experience with olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax. Small series but providing useful information for a common scenario in the clinic.”

Source: Jorge Cortes/X

Alice Mims Andrew H. Wei Anthony Schwarer Anthony Schwarer and Justin M. Watts Brian A. Jonas cancer Gail J. Roboz Gary Schiller Jorge Cortes Justin M. Watts Karen WL. Yee Olutasidenib OncoDaily Oncology P. Brent Ferrell Pau Montesinos Pierre Fenaux Taylor and Francis Online venetoclax

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage